Table 33Body of evidence for pharmacological prophylaxis in obese patients

Author, YearOutcomesPatients (N)Risk of BiasDirectnessPrecisionConsistencyMagnitude of EffectStrength of Evidence
Dalteparin vs. Placebo (In Obese Patients)
Kucher, N., 2005 150VTE1118ModerateDirectImpreciseUnknown2.8% vs 4.3%; (RR, 0.64; 95% CI 0.32-1.28)Insufficient evidence to comment on effectiveness of dalteparin vs placebo in reducing Total VTE in obese patients
Kucher, N., 2005 150Mortality1118ModerateDirectImpreciseUnknown9.9% vs 8.6%, p=0.36Insufficient evidence to comment on effectiveness of Dalteparin vs placebo in reducing mortality in obese patients
Kucher, N., 2005 150Major bleeding1118ModerateDirectImpreciseUnknown0% vs 0.7%, p>0.99Insufficient evidence to comment on safety of Dalteparin vs placebo in reducing major bleeding in obese patients
Enoxaparin 40 mg Daily vs. 0.4 mg/kg In Obese Patients
Freeman A, 2012 151Percentage of patients achieving target anti-Factor Xa level20ModerateIndirectImpreciseUnknown19% vs 32%, p=NRInsufficient evidence to comment on effectiveness of enoxaparin 40 mg daily versus 0.4 mg/kg in achieving peak anti- Factor Xa level in obese patients
Enoxaparin 40 mg Daily vs. 0.5 mg/kg In Obese Patients
Freeman A, 2012 151Percentage of patients achieving target anti-Factor Xa level22ModerateIndirectPreciseUnknown19% vs 86%,p<0.001Insufficient evidence to comment on effectiveness of enoxaparin 40 mg daily versus 0.5 mg/kg in achieving peak anti- Factor Xa level in obese patients
Enoxaparin 0.4 mg/kg vs. 0.5 mg/kg In Obese Patients
Freeman A, 2012 151Percentage of patients achieving target anti-Factor Xa level20ModerateIndirectImpreciseUnknown32% vs 86%, p=NRInsufficient evidence to comment on effectiveness of enoxaparin 0.4 mg/kg versus 0.5 mg/kg in achieving peak anti- Factor Xa level in obese patients

From: Results

Cover of Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations
Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations [Internet].
Comparative Effectiveness Reviews, No. 116.
Singh S, Haut ER, Brotman DJ, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.